Mollipect (Bromhexine Hydrochloride, Ephedrine Hydrochloride)

Bromhexine acts as a mucolytic by stimulating serous secretions in the airways, breaking down mucus structure and lowering its viscosity. Ephedrine is a non‑selective adrenergic agonist that induces bronchodilation and vasoconstriction of nasal vessels, decreasing congestion. Together they improve mucus clearance and airway patency.

The appropriate dose of Mollipect is determined by the prescribing healthcare professional based on the patient’s age, weight, severity of symptoms, and overall medical condition. Dosage recommendations are not standardized in this summary; clinicians should follow local prescribing guidelines and product labeling.

Safety of Mollipect in pregnancy or lactation has not been definitively established. Healthcare providers should evaluate the potential benefits against possible risks before prescribing to pregnant or nursing women, and consider alternative therapies when appropriate.

To order Mollipect, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and the necessary import documentation.

Compared with simple expectorants, Mollipect combines a mucolytic (bromhexine) with a sympathomimetic decongestant (ephedrine), offering both mucus‑thinning and nasal decongestion. This dual action can be more effective for patients who have both productive cough and nasal blockage, whereas single‑component products address only one of those symptoms.

Mollipect should be stored at ambient temperature below 25 °C, in its original packaging, protected from moisture and direct sunlight. Keep the product out of reach of children and avoid exposing it to extreme heat or humidity to maintain its stability.

Mollipect is taken orally, usually as a tablet or capsule, with a glass of water. The exact administration instructions, including timing relative to meals, are provided by the prescribing clinician and should be followed as indicated on the product label.

Serious risks include hypertension, cardiac arrhythmias, severe allergic reactions such as anaphylaxis, and, rarely, seizures. Patients experiencing sudden high blood pressure, irregular heartbeats, rash with swelling, or convulsive episodes should seek immediate medical attention.

Mollipect should be avoided in individuals with known hypersensitivity to bromhexine, ephedrine, or any excipients, as well as in patients with uncontrolled hypertension, severe coronary artery disease, hyperthyroidism, or those taking monoamine oxidase inhibitors. Consultation with a healthcare professional is essential before initiating therapy.